Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS
Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS
Sponsor: Institute for Clinical Research
A NA clinical study on Relapsing-Remitting Multiple Sclerosis, this trial is ongoing. The trial is conducted by Institute for Clinical Research and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status NA
First recorded
Jan 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute for Clinical Research
For direct contact, visit the study record on ClinicalTrials.gov .